Skip to content

The changes of multiple evoked potentials (SSEP, MEP, BAEP) during the treatment of severe spontaneous intracerebral hemorrhage and their correlation with patients‘ prognosis

The changes of multiple evoked potentials (SSEP, MEP, BAEP) during the treatment of severe spontaneous intracerebral hemorrhage and their correlation with patients’ prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051498
Enrollment
Unknown
Registered
2021-09-24
Start date
2022-04-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracerebral hemorrhage

Interventions

Sponsors

Liaocheng People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with spontaneous supratentorial hemorrhage: head CT shows that the hematoma is located in the supratentorial cerebellum, except for patients with infratentorial or brainstem hemorrhage, the hematoma can rupture into the lateral ventricle, third ventricle or fourth ventricle, and may be accompanied by obstructive hydrocephalus; 2. Calculate the amount of intraparenchymal hematoma by head CT (ABC calculation method, intraventricular hemorrhage is not included in the amount of hemorrhage); 3. Glasgow coma score 3-8 on admission; the hematoma volume exceeds 30ml; 4. Time from onset to admission <= 24 hours; 5. The patient's age is 18-80 years old; 6. Agree to accept the test and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary brainstem hemorrhage caused by aneurysm, arteriovenous malformation, cavernous vascular malformation or tumor stroke was excluded by CTA or MRA or DSA; 2. Serious impairment of coagulation function, which cannot be corrected in a short time; 3. Multiple intracranial hemorrhage; 4. Severe craniocerebral injury; 5. Patients with severe late brain herniation (bilateral mydriasis is fixed, with or without spontaneous breathing); 6. Liver and kidney failure or combined with systemic malignant tumor; 7. History of mental disorder or neurological dysfunction in the past; 8. The follow-up has not been completed; 9. Pregnant patients; 10. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
somatosensory;action;

Countries

China

Contacts

Public ContactZhang Shubao

Liaocheng People's Hospital

zsbysn@163.com+86 13346253329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026